Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Tradjenta, Trajenta Duo
Linagliptin is an oral anti-diabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor class used to treat type 2 diabetes. It works by increasing the levels of incretin hormones, which stimulate the release of insulin after meals and reduce the release of glucagon from the liver. This helps lower blood sugar levels.
For the treatment of type 2 diabetes mellitus.
Outcome:
Increased risk of hypoglycemia
Mechanism:
Additive hypoglycemic effects
Outcome:
Potential increased risk of hypoglycemia
Mechanism:
Alcohol can enhance the hypoglycemic effects of linagliptin.
Outcome:
Potential increase in digoxin levels
Mechanism:
Linagliptin may slightly inhibit P-glycoprotein, which transports digoxin.
Most likely new formulation: Combination therapy with other antidiabetic agents (Year: 2025, 70% confidence)
Based on current usage trends and clinical trial data, there is a low likelihood (<5%) of any major regulatory changes for linagliptin in the next 2 years.
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Xanthine